Edition:
United States

VistaGen Therapeutics Inc (VTGN.OQ)

VTGN.OQ on NASDAQ Stock Exchange Capital Market

1.47USD
25 May 2018
Change (% chg)

$0.50 (+51.55%)
Prev Close
$0.97
Open
$1.67
Day's High
$1.76
Day's Low
$1.41
Volume
3,919,933
Avg. Vol
131,729
52-wk High
$2.65
52-wk Low
$0.69

Chart for

About

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II... (more)

Overall

Beta: -0.51
Market Cap(Mil.): $33.67
Shares Outstanding(Mil.): 22.90
Dividend: --
Yield (%): --

Financials

  VTGN.OQ Industry Sector
P/E (TTM): -- 28.62 32.94
EPS (TTM): -1.38 -- --
ROI: -151.49 13.26 12.79
ROE: -218.33 14.99 14.67

BRIEF-VistaGen Therapeutics Reports Qtrly Loss Per Share $‍0.25​

* VISTAGEN THERAPEUTICS REPORTS THIRD QUARTER FISCAL 2018 FINANCIAL RESULTS

Feb 12 2018

BRIEF-Vistagen Therapeutics ‍Prepares To Initiate Its Phase 2 Study Of Av-101 For Major Depressive Disorder​

* VISTAGEN THERAPEUTICS INC - ‍PREPARES TO INITIATE ITS PHASE 2 STUDY OF AV-101 FOR MAJOR DEPRESSIVE DISORDER​ Source text for Eikon: Further company coverage:

Jan 29 2018

BRIEF-Vistagen Therapeutics Receives FDA Fast Track Designation For Av-101 For Treatment Of Major Depressive Disorder

* VISTAGEN THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR AV-101 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

Jan 03 2018

BRIEF-Intracoastal Capital Llc Reports A 9.99 Pct Passive Stake In Vistagen Therapeutics As Of Dec 13

* REPORTS a 9.99 PCT PASSIVE STAKE IN VISTAGEN THERAPEUTICS INC : AS OF DEC 13 - SEC FILING Source text: (http://bit.ly/2CNm098) Further company coverage:

Dec 20 2017

BRIEF-Sabby Management LLC Reports A 9.15 Pct Passive Stake In Vistagen Therapeutics

* SABBY MANAGEMENT LLC REPORTS A 9.15 PCT PASSIVE STAKE IN VISTAGEN THERAPEUTICS INC AS OF DEC 11 - SEC FILING Source text: (http://bit.ly/2ksLZuU) Further company coverage:

Dec 14 2017

Competitors

Earnings vs. Estimates